Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?

Cancers

Laura Longo¹  Daniela Cristina Vitale¹  Lucia Gozzo¹  Serena Brancati¹  Filippo Drago¹  Giovanni Luca Romano²  Calogero Vetro³  Ilaria Dulcamare³  Cinzia Maugeri³  Marina Parisi³  Francesco Di Raimondo³ 

[1] Clinical Pharmacology Unit, Regional Pharmacovigilance Centre, University Hospital of Catania, 95123 Catania, Italy;Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy;Haematology Unit, A.O.U. Policlinico “G. Rodolico-S. Marco”, 95123 Catania, Italy;

关键词: venetoclax;    acute myeloid leukemia;    relapsed/refractory;    off-label;    regulatory issue;   

DOI  :  10.3390/cancers14010022

来源: DOAJ

【 摘 要 】

Despite the progress in the development of new therapeutic strategies, relapsed/refractory (R/R) acute myeloid leukemia (AML) still represents a high unmet medical need. Treatment options in this setting include enrollment into clinical trials, allogeneic stem cell transplantation and/or targeted therapy. Nevertheless, it is associated with poor outcomes. Thus, the development of new treatments, which could ameliorate the prognosis of these patients with a good safety profile are highly demanded. Recently, venetoclax (VEN) has been approved for naïve AML patients unfit for intensive chemotherapy. In this regard, regimens including VEN could represent a valuable treatment option even in those with R/R disease and several studies have been conducted to demonstrate its role in this clinical setting. This review aims to summarize the current evidence on the use of VEN regimens in the treatment of R/R AML.

【 授权许可】

Unknown